New analysis from Frost & Sullivan, U.S. Angioplasty and Vascular Closure Devices Markets, reveals that the market earned revenues of $1.25 billion in 2005 and estimates to reach $ 1.89 billion in 2012.
If you are interested in a virtual brochure, which provides financial executives, investment professionals, marketing directors, business development executives, and other industry participants an overview of the latest analysis of the U.S. Angioplasty and Vascular Closure Devices Markets, then send an e-mail to Melina Trevino, Corporate Communications, with your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information by email upon receipt of the above information.
“The angioplasty balloon catheter market is driven largely by the benefits of the angioplasty procedure over other highly invasive surgical procedures,” says Frost & Sullivan Research Associate Archana Swathy. “Also, cardiovascular disease is the largest life threatening disease in the United States since 1900; in 2003 alone, about 71.3 million people were affected by it.”
Angioplasty, being a minimally invasive interventional procedure, offers significant benefits compared to more invasive surgeries. For example, angioplasty significantly reduces the risk of infection, and enhances patient comfort by reducing pain and trauma. Furthermore, the overall procedure cost is also comparatively lower than more invasive surgeries. Combined with shorter recovery times, which reduce hospitalization costs - angioplasty has been recognized as a very convenient therapeutic option.
In both the angioplasty catheter market and vascular closure market, two or three companies dominate a major portion of the market. These large companies have an edge over the smaller companies due to established resources to guide their products through FDA approvals, patent protection litigations, and the ability to conduct large-scale clinical trials to demonstrate product efficacy.
“In this highly competitive market the domination of larger industry players, with their command of resources, are curbing the growth of emerging companies,” explains Swathy. “Smaller companies are overshadowed as these dominant participants direct their products right from gaining FDA approval to the final clinical-trial stage.”
The adoption of strategic marketing trends and the development of novel technologies—that are superior than the ones present in the market, can help emerging participants get a better stand in the market.
The U.S. Angioplasty and Vascular Closure Devices Markets is part of the Medical Devices Growth Partnership Service, and it provides a detailed analysis market drivers, restraints, and trends that are impacting the angioplasty and vascular closure devices markets. It also includes a thorough examination of the following technologies: angioplasty balloon catheters and vascular closure devices. Interviews are available to the press.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.